Find a Clinical Trial by Adult Cancer Type

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

Back to Adult Cancers

Cancer Type: Esophagus

42 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Show: Only Esophagus specific trials All trials that include Esophagus

Doctor	Protocol No.	Title
Asher, Arash	IIT2019-08-ASHER-VOXXSOCK	IIT2019-08-ASHER-VOXXSOCK: Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy: A Double Blind, Randomized, Controlled Crossover Trial (IRB#236)
Balmanoukian, Ani	AB154CSP0001	AB154CSP0001: A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants with Advanced Malignancies (IRB#57210)
Chiu, Vi K.	DEK-DKK1-P205	DEK-DKK1-P205: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish) (IRB#782)
Gresham, Gillian	IIT2018-19-GRESH-DIGISTEP	Digitally-captured Step counts for Evaluating Performance Status in Advanced Cancer Patients: A single cohort, prospective trial (Digi-STEPS) (IRB#55271)
Gresham, Gillian	IIT2020-13-GRESHAM-ELLY	IIT2020-13-GRESHAM-ELLY: Evaluating the effect of a mobile audio companion (Elly) to reduce anxiety in cancer patients (IRB#943)
Gutierrez, Rodolfo	TYR-219-01	A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced solid tumors and Head and Neck cancer (IRB#907)
Gutierrez, Rodolfo	IMC-C103C-101	A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients with Advanced MAGE-A4-positive Cancer (IRB#56562)
Hamid, Omid	212214	212214: A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors (IRB#688)
Hamid, Omid	D8510C00001	D8510C00001: A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid Tumors (IRB#57295)
Hamid, Omid	CIBI322A102	CIBI322A102 A Phase 1a study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with advanced malignant tumors. (IRB#1021)
Hamid, Omid	R3767-ONC-1613	R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies (IRB#48031)
Hamid, Omid	RTX-240-01	PHASE 1/2 STUDY OF RTX-240 MONOTHERAPY (IRB#596)
Hamid, Omid	BA3021-001	BA3021-001: A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 in Patients with Advanced Solid Tumors (IRB#0393)
Hamid, Omid	BA3011-001	BA3011-001: A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients with Advanced Solid Tumors( IRB#383)
Hamid, Omid	RTX-321-01	RTX-321-01: A Phase 1 Study of RTX-321 for the Treatment of Patients with Advanced Malignancies Associated with Human Papillomavirus-16 Infection (IRB#1150)
Hamid, Omid	ALKS4230-001	ALKS4230-001: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors- ARTISTRY-2 (001)(IRB#0539)
Hamid, Omid	TAPUR	Targeted Agent and Profiling Utilization Registry (TAPUR) Study (IRB#49119)
Hamid, Omid	TWT-101	TWT-101: A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies (IRB#819)
Hamid, Omid	587-00	587-00: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. (IRB#54410)
Hendifar, Andrew	RGX-202-001	RGX-202-001: A Phase 1 Study of RGX-202-01, a Small Molecule Inhibitor of the Creatine Transporter, SLC6a8, with or without FOLFIRI in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (IRB#55176)
Hendifar, Andrew	MK-7339-002	MK7339-002: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (IRB#57241)
Hendifar, Andrew	18-0402	18-0402: A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects with Advanced Solid Tumors and Pancreatic Cancer using Combination Therapy (IRB#185)
Hitchins, Megan	IIT2017-13-HITCHINS-UCFC	IIT2017-13-HITCHINS-UCFC: Identifying cryptic causes for high-risk hereditary cancer syndromes and their role in cancer causation. (IRB#49624)
Labadzhyan, Artak	IIT2016-09-LABADZHYAN-ICI	IIT2016-09-LABADZHYAN-ICI: Prospective study of predictive markers and changes in specific endocrine hormones in patients with metastatic cancers treated with immune checkpoint inhibitors. (IRB#45026)
Mita, Alain	P1719-SUR-Z11	P1719-SUR-Z11: A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid Tumours. (IRB#57155)
Mita, Monica	SQZ-PBMC-HPV-101	SQZ-PBMC-HPV-101: A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination with Atezolizumab in HLA-A*02+ Patients with HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors (IRB#577)
Mita, Monica	GEN-602-CT-101	GEN-602-CT-101: A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Given orally on a daily x 21 days followed by 7 Days off schedule in patients with Advanced Solid Tumors or Lymphoma (IRB#56184)
Mita, Monica	INCB106385-102	INCB106385-102: A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors (IRB#1094)
Mita, Monica	LNS-101	LNS-101: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer (IRB#315)
Mita, Monica	M16-573	M16-573: A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid tumors (IRB#24)
Mita, Monica	MT-5111-001	MT-5111_001: A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors (IRB#144)
Mita, Monica	OBT076-001	OBT076-001: A Phase 1, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of OBT076, a CD205-directed antibody drug conjugate, in recurrent and/or metastatic CD205-positive solid tumors and in women with CD205-positive HER2-negative metastatic breast cancer (IRB#076)
Mita, Alain	BNT411-01	BNT411-01: Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC) (IRB#578)
Mita, Monica	8379643	8379643: A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Evidence of Antitumor Activity of ZZ06 in Adult Patients with Advanced EGFR positive Solid Tumor Malignancies (IRB#632)
Mita, Alain	ASTX029-01	ASTX029-01: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors (IRB#54467)
Posadas, Edwin	BB-UOP-42197-BLOOD-BANK	Urologic Oncology Program Blood Specimen Repository (IRB # 42197)
Reckamp, Karen	ELVCAP-001-01	ELVCAP-001-01: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (IRB#862)
Shiao, Stephen	IIT2016-18-SHIAO-NEOADSRS	IIT2016-18-SHIAO-NEOADSRS: Neoadjuvant radiosurgery for the treatment of metastatic brain tumors (IRB#47027)
Sicotte, Nancy	BA39731	BA39731: An Observational Study of Ocrelizumab-Treated Patients With Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies (Verismo Study) (IRB#482)
Wentzel, Kristopher	9801-CL-0101	9801-CL-0101: A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors (IRB#57758)
Wentzel, Kristopher	8951-CL-0103	A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression. (IRB#52384)
Wentzel, Kristopher	XL184-021	XL184-021: A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (IRB#56332)

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.

Phase I

Researchers test an experimental drug or treatment in a small group of people (20-80), to evaluate its safety and identify side effects. Often these trials are not disease specific and may include more than one type of cancer.

Phase II

The experimental drug or treatment is administered to a larger group of people (100-300) to determine its effectiveness and to further evaluate its safety.

Phase III

The experimental drug or treatment is administered to larger groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatment, and collect information that will allow the experimental drug or treatment to be used safely.